Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TDP2 | O95551 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7146843 | 0.89 | LMNA (0.49) | JAK2LMNATDP2PDE4DKDM4E | |
| SCHEMBL7039193 | 0.88 | LMNA (0.61) | JAK2LMNAPDE4DKDM4EMAPT | |
| SCHEMBL6871008 | 0.86 | JAK2 (0.51) | JAK2LMNAPDE4DKDM4EMAPT | |
| SCHEMBL7143995 | 0.86 | ADORA1 (0.53) | TDP2PDE4DKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL7143130 | 0.85 | PDE4D (0.52) | JAK2LMNAPDE4DKDM4EMAPT | |
| SCHEMBL7149099 | 0.84 | KDM4E (0.55) | JAK2LMNAPDE4DKDM4EMAPT | |
| SCHEMBL7146900 | 0.82 | PDE4D (0.50) | JAK2LMNAPDE4DKDM4EMAPT | |
| SCHEMBL7762456 | 0.82 | SMN1; SMN2 (0.45) | JAK2PDE4DMAPTJAK1SMN1; SMN2 | |
| SCHEMBL7145623 | 0.81 | LMNA (0.48) | JAK2LMNAPDE4DKDM4EMAPT | |
| SCHEMBL7151579 | 0.81 | LMNA (0.46) | JAK2LMNAPDE4DKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |